NO303503B1 - Polynukleotid i stand til Õ hybridisere til en HCV-sekvens i en analytt polynukleotidkjede, HCV-testsett samt anvendelse av nevnte polynukleotid - Google Patents
Polynukleotid i stand til Õ hybridisere til en HCV-sekvens i en analytt polynukleotidkjede, HCV-testsett samt anvendelse av nevnte polynukleotid Download PDFInfo
- Publication number
- NO303503B1 NO303503B1 NO914517A NO914517A NO303503B1 NO 303503 B1 NO303503 B1 NO 303503B1 NO 914517 A NO914517 A NO 914517A NO 914517 A NO914517 A NO 914517A NO 303503 B1 NO303503 B1 NO 303503B1
- Authority
- NO
- Norway
- Prior art keywords
- hcv
- sequence
- polynucleotide
- sequences
- cdna
- Prior art date
Links
- 239000002157 polynucleotide Substances 0.000 title claims abstract description 114
- 108091033319 polynucleotide Proteins 0.000 title claims abstract description 113
- 102000040430 polynucleotide Human genes 0.000 title claims abstract description 113
- 239000012491 analyte Substances 0.000 title claims description 17
- 238000012360 testing method Methods 0.000 title claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 165
- 239000002773 nucleotide Substances 0.000 claims description 164
- 238000003752 polymerase chain reaction Methods 0.000 claims description 104
- 230000000295 complement effect Effects 0.000 claims description 79
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 47
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 45
- 229920001184 polypeptide Polymers 0.000 claims description 44
- 238000001514 detection method Methods 0.000 claims description 33
- 108091034117 Oligonucleotide Proteins 0.000 claims description 31
- 208000015181 infectious disease Diseases 0.000 claims description 28
- 108700026244 Open Reading Frames Proteins 0.000 claims description 24
- 210000004369 blood Anatomy 0.000 claims description 17
- 239000008280 blood Substances 0.000 claims description 17
- 238000000338 in vitro Methods 0.000 claims description 12
- 230000002458 infectious effect Effects 0.000 claims description 11
- 239000010836 blood and blood product Substances 0.000 claims description 6
- 229940125691 blood product Drugs 0.000 claims description 4
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 abstract description 499
- 241000700605 Viruses Species 0.000 abstract description 37
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 10
- 208000005176 Hepatitis C Diseases 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 description 229
- 239000013615 primer Substances 0.000 description 220
- 239000000523 sample Substances 0.000 description 214
- 238000000034 method Methods 0.000 description 193
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 117
- 239000000047 product Substances 0.000 description 67
- 150000007523 nucleic acids Chemical class 0.000 description 64
- 102000039446 nucleic acids Human genes 0.000 description 60
- 108020004707 nucleic acids Proteins 0.000 description 60
- 238000009396 hybridization Methods 0.000 description 54
- 235000001014 amino acid Nutrition 0.000 description 51
- 108020004414 DNA Proteins 0.000 description 50
- 210000002381 plasma Anatomy 0.000 description 50
- 150000001413 amino acids Chemical class 0.000 description 49
- 238000004519 manufacturing process Methods 0.000 description 41
- 125000003275 alpha amino acid group Chemical group 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 31
- 238000002955 isolation Methods 0.000 description 31
- 241000710831 Flavivirus Species 0.000 description 30
- 241000282577 Pan troglodytes Species 0.000 description 30
- 210000002966 serum Anatomy 0.000 description 30
- 108010076039 Polyproteins Proteins 0.000 description 29
- 108091028043 Nucleic acid sequence Proteins 0.000 description 26
- 230000027455 binding Effects 0.000 description 26
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 210000004185 liver Anatomy 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 241000282579 Pan Species 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 18
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- 238000011144 upstream manufacturing Methods 0.000 description 17
- 108020004635 Complementary DNA Proteins 0.000 description 16
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 16
- 238000010367 cloning Methods 0.000 description 16
- 230000003612 virological effect Effects 0.000 description 16
- 230000000875 corresponding effect Effects 0.000 description 15
- 102100034343 Integrase Human genes 0.000 description 14
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 14
- 230000003321 amplification Effects 0.000 description 14
- 239000012472 biological sample Substances 0.000 description 14
- 238000003199 nucleic acid amplification method Methods 0.000 description 14
- 239000012071 phase Substances 0.000 description 14
- 239000012634 fragment Substances 0.000 description 13
- 230000010076 replication Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000000211 autoradiogram Methods 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 230000008685 targeting Effects 0.000 description 12
- 108020004705 Codon Proteins 0.000 description 11
- 108010067770 Endopeptidase K Proteins 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
- 230000001154 acute effect Effects 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 108020000999 Viral RNA Proteins 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 10
- 238000012163 sequencing technique Methods 0.000 description 10
- 238000013519 translation Methods 0.000 description 10
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 9
- 108091035707 Consensus sequence Proteins 0.000 description 9
- 230000000692 anti-sense effect Effects 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- 108091036078 conserved sequence Proteins 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 208000006454 hepatitis Diseases 0.000 description 9
- 231100000283 hepatitis Toxicity 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 239000002987 primer (paints) Substances 0.000 description 9
- 238000003127 radioimmunoassay Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 241000710842 Japanese encephalitis virus Species 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 238000012317 liver biopsy Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- 238000010839 reverse transcription Methods 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 7
- 108010082126 Alanine transaminase Proteins 0.000 description 7
- 241000710781 Flaviviridae Species 0.000 description 7
- 101710128560 Initiator protein NS1 Proteins 0.000 description 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 7
- 101710144127 Non-structural protein 1 Proteins 0.000 description 7
- 241000276498 Pollachius virens Species 0.000 description 7
- 108091081021 Sense strand Proteins 0.000 description 7
- 241000710886 West Nile virus Species 0.000 description 7
- 241000710772 Yellow fever virus Species 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 238000010804 cDNA synthesis Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 238000004925 denaturation Methods 0.000 description 7
- 230000036425 denaturation Effects 0.000 description 7
- 229930182817 methionine Natural products 0.000 description 7
- 238000006116 polymerization reaction Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 229940051021 yellow-fever virus Drugs 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
- 238000002105 Southern blotting Methods 0.000 description 6
- 108010006785 Taq Polymerase Proteins 0.000 description 6
- -1 antibodies Proteins 0.000 description 6
- ASCHNMXUWBEZDM-UHFFFAOYSA-N chloroperoxyl Inorganic materials [O]OCl ASCHNMXUWBEZDM-UHFFFAOYSA-N 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 239000001226 triphosphate Substances 0.000 description 6
- 235000011178 triphosphate Nutrition 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 208000001490 Dengue Diseases 0.000 description 5
- 206010012310 Dengue fever Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 238000012300 Sequence Analysis Methods 0.000 description 5
- 101710172711 Structural protein Proteins 0.000 description 5
- 208000025729 dengue disease Diseases 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001502 gel electrophoresis Methods 0.000 description 5
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 208000019423 liver disease Diseases 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 239000003155 DNA primer Substances 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 241000710924 Togaviridae Species 0.000 description 4
- 208000003152 Yellow Fever Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 241001493065 dsRNA viruses Species 0.000 description 4
- 231100000234 hepatic damage Toxicity 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 230000008818 liver damage Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 4
- 241000713838 Avian myeloblastosis virus Species 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 241000724709 Hepatitis delta virus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101710163270 Nuclease Proteins 0.000 description 3
- 238000009004 PCR Kit Methods 0.000 description 3
- 102000015623 Polynucleotide Adenylyltransferase Human genes 0.000 description 3
- 108010024055 Polynucleotide adenylyltransferase Proteins 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000005547 deoxyribonucleotide Substances 0.000 description 3
- 235000021186 dishes Nutrition 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000007899 nucleic acid hybridization Methods 0.000 description 3
- 238000002515 oligonucleotide synthesis Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000000379 polymerizing effect Effects 0.000 description 3
- 230000033458 reproduction Effects 0.000 description 3
- 239000003161 ribonuclease inhibitor Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000005199 ultracentrifugation Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical class C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 2
- 101710204837 Envelope small membrane protein Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- 208000037262 Hepatitis delta Diseases 0.000 description 2
- 206010019791 Hepatitis post transfusion Diseases 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 101710145006 Lysis protein Proteins 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 108091027568 Single-stranded nucleotide Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 241000589500 Thermus aquaticus Species 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000337 buffer salt Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 208000029570 hepatitis D virus infection Diseases 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229940063675 spermine Drugs 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- AUIJUTGLPVHIRT-FXQIFTODSA-N Arg-Ser-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)CN=C(N)N AUIJUTGLPVHIRT-FXQIFTODSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000714198 Caliciviridae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000295146 Gallionellaceae Species 0.000 description 1
- PYFIQROSWQERAS-LBPRGKRZSA-N Gly-Trp-Gly Chemical compound C1=CC=C2C(C[C@H](NC(=O)CN)C(=O)NCC(O)=O)=CNC2=C1 PYFIQROSWQERAS-LBPRGKRZSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 208000002430 Multiple chemical sensitivity Diseases 0.000 description 1
- 101500006448 Mycobacterium bovis (strain ATCC BAA-935 / AF2122/97) Endonuclease PI-MboI Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000710778 Pestivirus Species 0.000 description 1
- JEBWZLWTRPZQRX-QWRGUYRKSA-N Phe-Gly-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O JEBWZLWTRPZQRX-QWRGUYRKSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000282860 Procaviidae Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- BERPCVULMUPOER-UHFFFAOYSA-N Quinolinediol Chemical compound C1=CC=C2NC(=O)C(O)=CC2=C1 BERPCVULMUPOER-UHFFFAOYSA-N 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 101800000684 Ribonuclease H Proteins 0.000 description 1
- 101710141795 Ribonuclease inhibitor Proteins 0.000 description 1
- 229940122208 Ribonuclease inhibitor Drugs 0.000 description 1
- 102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 231100000569 acute exposure Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- MCQILDHFZKTBOD-UHFFFAOYSA-N diethoxy-hydroxy-imino-$l^{5}-phosphane Chemical compound CCOP(N)(=O)OCC MCQILDHFZKTBOD-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- XEBWQGVWTUSTLN-UHFFFAOYSA-M phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000004018 waxing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35596189A | 1989-05-18 | 1989-05-18 | |
US45663789A | 1989-12-21 | 1989-12-21 | |
US50543590A | 1990-04-04 | 1990-04-04 | |
PCT/US1990/002853 WO1990014436A1 (en) | 1989-05-18 | 1990-05-18 | Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus |
Publications (3)
Publication Number | Publication Date |
---|---|
NO914517D0 NO914517D0 (no) | 1991-11-18 |
NO914517L NO914517L (no) | 1992-01-16 |
NO303503B1 true NO303503B1 (no) | 1998-07-20 |
Family
ID=27408242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO914517A NO303503B1 (no) | 1989-05-18 | 1991-11-18 | Polynukleotid i stand til Õ hybridisere til en HCV-sekvens i en analytt polynukleotidkjede, HCV-testsett samt anvendelse av nevnte polynukleotid |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0398748B1 (fi) |
JP (3) | JP2656996B2 (fi) |
AT (1) | ATE211772T1 (fi) |
AU (1) | AU638719B2 (fi) |
BG (1) | BG60348B2 (fi) |
CA (1) | CA2017157C (fi) |
DE (1) | DE69033891T2 (fi) |
DK (1) | DK0398748T3 (fi) |
ES (1) | ES2166749T3 (fi) |
FI (1) | FI105279B (fi) |
GE (1) | GEP20002164B (fi) |
HU (1) | HUT59964A (fi) |
LV (1) | LV10729B (fi) |
MC (1) | MC2188A1 (fi) |
NO (1) | NO303503B1 (fi) |
RO (1) | RO113059B1 (fi) |
WO (1) | WO1990014436A1 (fi) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6489246A (en) * | 1987-09-30 | 1989-04-03 | Sony Corp | Fixing method for color sorting mechanism of color cathode-ray tube |
US5698390A (en) | 1987-11-18 | 1997-12-16 | Chiron Corporation | Hepatitis C immunoassays |
US6171782B1 (en) | 1987-11-18 | 2001-01-09 | Chiron Corporation | Antibody compositions to HCV and uses thereof |
US6861212B1 (en) | 1987-11-18 | 2005-03-01 | Chiron Corporation | NANBV diagnostics and vaccines |
US5714596A (en) * | 1987-11-18 | 1998-02-03 | Chiron Corporation | NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus |
US5712088A (en) * | 1987-11-18 | 1998-01-27 | Chiron Corporation | Methods for detecting Hepatitis C virus using polynucleotides specific for same |
US6027729A (en) * | 1989-04-20 | 2000-02-22 | Chiron Corporation | NANBV Diagnostics and vaccines |
LU87861A1 (fr) | 1989-12-18 | 1991-10-08 | Wellcome Found | Agent viral |
US7166287B1 (en) | 1989-12-18 | 2007-01-23 | Glaxo Wellcome Inc. | Viral agent |
CA2044296A1 (en) * | 1990-06-12 | 1991-12-13 | Hiroaki Okamoto | Oligonucleotide primers, and their application for high-fidelity detection of non-a, non-b hepatitis virus |
US5747339A (en) * | 1990-06-25 | 1998-05-05 | Research Foundation For Microbial Diseases Of Osaka | Non-A, non-B hepatitis virus genomic CDNA and antigen polypeptide |
ES2069298T3 (es) * | 1990-06-30 | 1995-05-01 | Akzo Nobel Nv | Secuencias no-a no-b. |
ATE150086T1 (de) * | 1990-07-11 | 1997-03-15 | Shionogi & Co | Cdns-sequenz und detektion des hepatitis c-virus |
WO1992001714A1 (en) * | 1990-07-24 | 1992-02-06 | Yamanouchi Pharmaceutical Co., Ltd. | Non-a non-b hepatitis virus antigen |
CZ282573B6 (cs) * | 1990-08-10 | 1997-08-13 | Chiron Corporation | Způsob detekce HCV sekvence, souprava a reakční činidlo pro detekci HCV |
WO1992009634A1 (en) * | 1990-11-29 | 1992-06-11 | Toray Industries, Incorporated | Non-a non-b hepatitis virus antigen protein |
WO1992012992A2 (en) * | 1991-01-14 | 1992-08-06 | James N. Gamble Institute Of Medical Research | Basic structural immunogenic polypeptides having epitopes for hcv, antibodies, polynucleotide sequences, vaccines and methods |
IE65424B1 (en) * | 1991-03-01 | 1995-10-18 | Akzo Nv | Peptides immunochemically reactive with antibodies directed against hepatitis non-A non-B virus |
US5574132A (en) * | 1991-04-05 | 1996-11-12 | Biochem Immunosystems Inc. | Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV) |
EP0510952A1 (en) * | 1991-04-26 | 1992-10-28 | Immuno Japan Inc. | Oligonucleotide primers and their application for high-fidelity detection of non-a, non-b hepatitis virus |
FR2677372B1 (fr) | 1991-06-06 | 1994-11-10 | Pasteur Institut | Sequences nucleotidiques et peptidiques d'un isolat de virus de l'hepatite c, applications diagnostiques et therapeutiques. |
IT1249684B (it) * | 1991-07-19 | 1995-03-09 | Sorin Biomedica Spa | Epitopi della proteina env del virus dell'epatite c. |
ATE161291T1 (de) * | 1991-08-27 | 1998-01-15 | Hoffmann La Roche | Verfahren und reagenzien zum nachweis von hepatitis c |
WO1993005181A1 (en) * | 1991-09-12 | 1993-03-18 | Cedars-Sinai Medical Center | Direct detection of hepatitis c virus rna |
PL171489B1 (pl) * | 1991-09-13 | 1997-05-30 | Chiron Corp | Sposób wytwarzania kompozycji immunogenicznej reagujacej immunologicznie krzyzowo z wieloma izolatami HCV PL |
AU3063992A (en) * | 1991-11-07 | 1993-06-07 | Dade International Inc. | Epitope mapping ot the c33c region of hcv |
EP0610436B9 (en) | 1991-11-21 | 2003-03-26 | Common Services Agency | Hepatitis-c virus testing |
GB9204274D0 (en) * | 1992-02-28 | 1992-04-08 | Wellcome Found | Novel peptides |
US5866139A (en) * | 1992-06-04 | 1999-02-02 | Institut Pasteur | Nucleotide and peptide sequences of a hepatitis C virus isolate, diagnostic and therapeutic applications |
US6057093A (en) * | 1992-09-28 | 2000-05-02 | Chiron Corporation | Methods and compositions for controlling translation of HCV proteins |
JPH06153961A (ja) * | 1992-11-27 | 1994-06-03 | Imuno Japan:Kk | C型肝炎ウイルス部分遺伝子、ならびにc型肝炎ウイルス遺 伝子の高感度検出法 |
ATE249838T1 (de) | 1993-05-12 | 2003-10-15 | Chiron Corp | Konserviertes motiv der hepatitis c virus e2/ns1 region |
PT1510580E (pt) | 1994-07-29 | 2009-02-18 | Novartis Vaccines & Diagnostic | Polipéptido e2 truncado da hepatite c e métodos para a sua obtenção |
PT773957E (pt) * | 1994-07-29 | 2005-11-30 | Chiron Corp | Polipeptidos truncados e1 e e2 de hepatite c inovadores, e metodos de obtencao dos mesmos |
US5837442A (en) | 1995-11-29 | 1998-11-17 | Roche Molecular Systems, Inc. | Oligonucleotide primers for amplifying HCV nucleic acid |
ES2328536T3 (es) | 1997-05-06 | 2009-11-13 | Novartis Vaccines And Diagnostics, Inc. | Produccion intracelular de polipeptido e2 truncado de la hepatitis c. |
DE19832050C2 (de) * | 1998-07-16 | 2002-10-10 | Biotest Pharma Gmbh | Verfahren zum Nachweis von Hepatitis B- bzw. Hepatitis C-Virusgenomen in Plasmaproben und spezifische Primer |
EP2286792A1 (en) | 1999-02-26 | 2011-02-23 | Novartis Vaccines and Diagnostics, Inc. | Microemulsions with an adsorbent surface, comprising a microdroplet emulsion |
WO2000050078A1 (en) | 1999-02-26 | 2000-08-31 | Chiron Corporation | Use of bioadhesives and adjuvants for the mucosal delivery of antigens |
US7196066B1 (en) | 1999-11-03 | 2007-03-27 | Powderject Vaccines, Inc. | DNA-vaccines based on constructs derived from the genomes of human and animal pathogens |
US6630298B2 (en) * | 2000-06-15 | 2003-10-07 | Chiron Corporation | HCV antigen/antibody combination assay |
US7022830B2 (en) | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
KR100801123B1 (ko) | 2000-08-17 | 2008-02-05 | 트리펩 아베 | 리바비린 함유 백신 및 이것의 사용 방법 |
US6858590B2 (en) | 2000-08-17 | 2005-02-22 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
US6680059B2 (en) | 2000-08-29 | 2004-01-20 | Tripep Ab | Vaccines containing ribavirin and methods of use thereof |
US6586584B2 (en) | 2001-01-29 | 2003-07-01 | Becton, Dickinson And Company | Sequences and methods for detection of Hepatitis C virus |
EP1399183B1 (en) | 2001-05-31 | 2010-06-30 | Novartis Vaccines and Diagnostics, Inc. | Chimeric alphavirus replicon particles |
AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
US7501134B2 (en) | 2002-02-20 | 2009-03-10 | Novartis Vaccines And Diagnostics, Inc. | Microparticles with adsorbed polypeptide-containing molecules |
US7598421B2 (en) | 2002-05-08 | 2009-10-06 | Ucl Biomedica Plc | Materials for the delivery of biologically-active material to cells |
EP1585542B1 (en) | 2002-12-27 | 2012-06-13 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions containing phospholipid |
ES2382332T3 (es) | 2003-02-06 | 2012-06-07 | Aduro Biotech | Listeria atenuada para entrar en células no fagocíticas, vacunas que comprenden esta listeria y métodos de uso de las mismas |
AU2004224425B2 (en) | 2003-02-06 | 2010-06-24 | Aduro Biotech | Modified free-living microbes, vaccine compositions and methods of use thereof |
US7695725B2 (en) | 2003-02-06 | 2010-04-13 | Aduro Biotech | Modified free-living microbes, vaccine compositions and methods of use thereof |
US7731967B2 (en) | 2003-04-30 | 2010-06-08 | Novartis Vaccines And Diagnostics, Inc. | Compositions for inducing immune responses |
US7842289B2 (en) | 2003-12-24 | 2010-11-30 | Aduro Biotech | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
US20060165716A1 (en) | 2004-07-29 | 2006-07-27 | Telford John L | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
EP1802778B1 (en) | 2004-08-27 | 2011-10-05 | Novartis Vaccines and Diagnostics, Inc. | Hcv multiple epitope fusion antigens with modified proteolytic cleavage sites and uses thereof |
US7968697B2 (en) | 2005-05-25 | 2011-06-28 | Chrontech Pharma Ab | Hepatitis C virus non-structural NS3/4A fusion gene |
US20110136678A1 (en) * | 2006-10-20 | 2011-06-09 | Erwin Sablon | Methodology for analysis of sequence variations within the hcv ns3/4a genomic region |
US20090214593A1 (en) | 2007-08-16 | 2009-08-27 | Tripep Ab | Immunogen platform |
US8071561B2 (en) | 2007-08-16 | 2011-12-06 | Chrontech Pharma Ab | Immunogen platform |
US8815253B2 (en) | 2007-12-07 | 2014-08-26 | Novartis Ag | Compositions for inducing immune responses |
WO2009143085A1 (en) | 2008-05-19 | 2009-11-26 | Anza Therapeutics, Inc. | Compositions comprising prfa*mutant listeria and methods of use thereof |
CN102427828A (zh) | 2009-03-09 | 2012-04-25 | 威廉·亨利 | 含具有信号肽的细菌毒素作为载体的半抗原-载体缀合物和它们在免疫原性组合物中的用途 |
FI122954B (fi) | 2011-01-31 | 2012-09-14 | Teknoware Oy | LED-putkilamppu ja valaisinjärjestely |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
DE3886363T3 (de) * | 1987-11-18 | 2004-09-09 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | NANBV-Diagnostika |
US5191064A (en) * | 1988-09-30 | 1993-03-02 | The Research Foundation For Microbial Diseases (Osaka University) | Non-a, non-b hepatitis virus antigen peptide |
WO1990011089A1 (en) * | 1989-03-17 | 1990-10-04 | Chiron Corporation | Nanbv diagnostics and vaccines |
CA2032907C (en) * | 1989-12-22 | 2002-05-14 | Richard R. Lesniewski | Hepatitis c assay |
CA2079677A1 (en) * | 1990-04-03 | 1991-10-04 | Kenneth H. Burk | Purified hcv and hcv proteins and peptides |
-
1990
- 1990-05-18 DE DE69033891T patent/DE69033891T2/de not_active Expired - Lifetime
- 1990-05-18 DK DK90305421T patent/DK0398748T3/da active
- 1990-05-18 MC MC@@@@@@@@@@@@D patent/MC2188A1/xx unknown
- 1990-05-18 AU AU58123/90A patent/AU638719B2/en not_active Expired
- 1990-05-18 CA CA002017157A patent/CA2017157C/en not_active Expired - Lifetime
- 1990-05-18 GE GE1876A patent/GEP20002164B/en unknown
- 1990-05-18 HU HU904754A patent/HUT59964A/hu unknown
- 1990-05-18 ES ES90305421T patent/ES2166749T3/es not_active Expired - Lifetime
- 1990-05-18 WO PCT/US1990/002853 patent/WO1990014436A1/en active IP Right Grant
- 1990-05-18 JP JP2508534A patent/JP2656996B2/ja not_active Expired - Lifetime
- 1990-05-18 AT AT90305421T patent/ATE211772T1/de not_active IP Right Cessation
- 1990-05-18 RO RO149205A patent/RO113059B1/ro unknown
- 1990-05-18 EP EP90305421A patent/EP0398748B1/en not_active Expired - Lifetime
-
1991
- 1991-11-18 NO NO914517A patent/NO303503B1/no not_active IP Right Cessation
- 1991-11-18 FI FI915443A patent/FI105279B/fi active
- 1991-11-18 BG BG95495A patent/BG60348B2/bg unknown
-
1993
- 1993-06-01 LV LVP-93-456A patent/LV10729B/en unknown
-
1996
- 1996-10-30 JP JP30570796A patent/JP3701754B2/ja not_active Expired - Lifetime
-
1997
- 1997-05-19 JP JP14598597A patent/JP3698520B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
BG60348B2 (bg) | 1994-09-30 |
GEP20002164B (en) | 2000-07-10 |
AU5812390A (en) | 1990-12-18 |
HU904754D0 (en) | 1992-01-28 |
DE69033891D1 (de) | 2002-02-21 |
LV10729B (en) | 1995-12-20 |
JPH05500155A (ja) | 1993-01-21 |
JPH1089A (ja) | 1998-01-06 |
JPH10113176A (ja) | 1998-05-06 |
EP0398748A3 (en) | 1991-10-23 |
DE69033891T2 (de) | 2002-08-29 |
LV10729A (lv) | 1995-06-20 |
JP2656996B2 (ja) | 1997-09-24 |
AU638719B2 (en) | 1993-07-08 |
CA2017157C (en) | 2003-07-29 |
EP0398748A2 (en) | 1990-11-22 |
FI915443A0 (fi) | 1991-11-18 |
ES2166749T3 (es) | 2002-05-01 |
RO113059B1 (ro) | 1998-03-30 |
EP0398748B1 (en) | 2002-01-09 |
NO914517L (no) | 1992-01-16 |
HUT59964A (en) | 1992-07-28 |
JP3701754B2 (ja) | 2005-10-05 |
NO914517D0 (no) | 1991-11-18 |
CA2017157A1 (en) | 1990-11-18 |
DK0398748T3 (da) | 2002-03-18 |
WO1990014436A1 (en) | 1990-11-29 |
JP3698520B2 (ja) | 2005-09-21 |
ATE211772T1 (de) | 2002-01-15 |
MC2188A1 (fr) | 1992-09-16 |
FI105279B (fi) | 2000-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO303503B1 (no) | Polynukleotid i stand til Õ hybridisere til en HCV-sekvens i en analytt polynukleotidkjede, HCV-testsett samt anvendelse av nevnte polynukleotid | |
US5863719A (en) | Methods for detecting hepatitis C virus using polynucleotides specific for same | |
US5714596A (en) | NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus | |
EP0543924B1 (en) | Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus | |
JP2656995B2 (ja) | Nanbvの診断用薬 | |
AU2003218111B2 (en) | Methods and compositions for identifying and characterizing hepatitis C | |
RU2145635C1 (ru) | Олигомер (варианты), способ обнаружения последовательности hcv (варианты), набор для обнаружения, способ получения крови | |
KR100491995B1 (ko) | 일본인으로부터의 이-형 간염 바이러스로부터 유래하는폴리누클레오티드 프로브 및 프라이머, 이들을 갖는 칩,이들을 갖는 키트, 및 이들에 의한 이-형 간염 바이러스를검출하는 방법 | |
Stuyver et al. | The use of a Line Probe Assay as a tool to detect new types or subtypes of the hepatitis C virus | |
PT94081B (pt) | Diagnosticos para o nambv: polinucleotidos uteis na deteccao do virus da hepatite c | |
Gerotto | The 5'UTR of the Hepatitis C virus: Structural, Functional Studies and Clinical Significance | |
IL143675A (en) | Polynucleotide capable of hybridizing to a complement of a genomic sequence of hepatitis c virus, polynucleotide probe comprising said polynucleotide and methods using said probe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |